Pancreatic Ductal Adenocarcinoma (PDAC)
Patient Condition
The 61-year-old patient was diagnosed with pancreatic ductal adenocarcinoma stage IV (liver metastasis), KRAS G12R mutation, and BRCA2 mutation positive. It progressed after 8 cycles of first-line FOLFIRINOX treatment and progressed again after 3 cycles of second-line gemcitabine + albumin paclitaxel. At the time of diagnosis, CA19 -9 was 1200 U/mL, ECOG score was 2 points, and body weight dropped by 8kg in 3 months.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Precise treatment with PARP inhibitors | ||
| Maintenance treatment and surgical evaluation | ||
| Postoperative maintenance follow-up |
Treatment Outcome
| before | Pancreatic cancer stage IV, failed double-track chemotherapy, BRCA2 + but not targeted drug, ECOG 2 |
|---|---|
| after | R0 Whipple operation was successful, and survived disease-free 18 months after surgery, ECOG score 0 |
| highlight | BRCA2 precision treatment achieves translational surgery, achieving long-term survival for stage IV pancreatic cancer |